TG Therapeutics, Inc. $TGTX Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 56.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 227,934 shares of the biopharmaceutical company’s stock after buying an additional 81,907 shares during the quarter. JPMorgan Chase & Co. owned about 0.14% of TG Therapeutics worth $8,234,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics during the second quarter valued at about $25,000. Danske Bank A S acquired a new stake in TG Therapeutics in the 3rd quarter worth approximately $25,000. Optiver Holding B.V. grew its position in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 732 shares during the last quarter. Bessemer Group Inc. grew its position in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in TG Therapeutics during the 3rd quarter valued at approximately $34,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. cut their target price on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $31.75 on Monday. The company has a 50 day simple moving average of $29.76 and a two-hundred day simple moving average of $31.49. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 11.46 and a beta of 1.87. The company has a current ratio of 4.10, a quick ratio of 3.29 and a debt-to-equity ratio of 0.38. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The business had revenue of $192.57 million during the quarter, compared to analyst estimates of $192.15 million. During the same quarter in the previous year, the company earned $0.15 EPS. The firm’s revenue was up 78.0% compared to the same quarter last year. As a group, analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.